摘要
目的观察丹参川芎嗪对乙型肝炎大鼠病理形态学及TNF-α、TGF-β1表达影响。方法选择雄性SD大鼠,随机分为对照组(A)、模型组(B)和丹参川芎嗪组(C),每组10只;静脉注射乙型肝炎病毒抗原复制肝炎模型,C组腹腔注射丹参川芎嗪,连续给药3周;免疫组化法检测肝组织TNF-α、TGF-β1表达,ELISA法测定血清TNF-α、TGF-β1、HA、PCⅢ、LN,HE染色观察肝组织病理形态。结果与A组比较,B组ALT、AST、HA、PCⅢ、LN、TNF-α、TGF-β1明显升高;TNF-α、TGF-β1表达增加,肝组织病理损伤明显;C组ALT、AST、HA、PCⅢ、LN、TNF-α、TGF-β1明显低于B组;TNF-α、TGF-β1表达降低,肝组织病理损伤显著改善,上述差异均有统计学意义(P<0.05)。结论丹参川芎嗪可改善乙型肝炎大鼠肝纤维化程度,其作用可能与下调TNF-α、TGF-β1表达有关。
Objective To investigate the effect of Salvia miltiorrhiza ligustrazine on ppathological changes in liver tissue and expression of transforming growth factor-β1（TGFβ1）,tumor necrosis factor-α（TNF-α） in rat with hepatitis B.Methods 7-week-old male SD rats were randomly divided into control group（A）,model group（B）,Salvia Ligustrazine group（C）,with 10 rats in each group.Rats were injected with hepatitis B virus antigen to establish hepatitis model.Rats in group C were injected with Salvia Ligustrazine for consecutive three weeks.Expression of TNF-α,TGF-β1 in liver tissue were detected by immunohistochemistry method.The levels of TNF-α,TGF-β1,hyaluronic acid（HA）,procollagen type Ⅲ（PCⅢ）,laminin（LN） in serum were detected by ELISA method.Pathological changes in liver tissue were detected by HE staining.Results Compared with the group A,the levels of ALT,AST,HA,PCⅢ,LN,TNF-α,TGF-β1 in serum of group B were significantly higher,and expressions of TNF-α,TGF-β1 in liver tissue increased.Liver pathology in model group was obvious.The levels of ALT,AST,HA,PCⅢ,LN,TNF-α,TGF-β1 in serum of group C were significantly lower than that in the model group.The expression of TNF-α,TGF-β1 in liver tissue decreased,liver histopathology injury significantly improved,with the differences statistically significant（P〈0.05）.Conclusion The results show that Salvia Ligustrazine can improve the expression of liver fibrosis induced by hepatitis B,which may be related to the expression reduce of TNF-α,TGF-β1.
作者
吴晓瑛
荀运浩
吕铁锋
WU Xiao-ying XUN Yun-hao LV Tie-feng(The 5^th Department of Internal Medicine, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China)
出处
《中国卫生检验杂志》
CAS
2017年第4期498-501,共4页
Chinese Journal of Health Laboratory Technology
基金
浙江省中医药科技计划项目(2014ZA089)
